MRNA Mar 2025 145.000 call

OPR - OPR Delayed Price. Currency in USD

Add to watchlist

26.60

-2.53

(-8.69%)

At close: 10:56AM EDT

Zacks
Moderna's (MRNA) Next-Gen COVID-19 Jab Study Meets Efficacy Goal
Data from a late-stage study shows that Moderna's (MRNA) next-generation COVID-19 vaccine achieved non-inferior vaccine efficacy against COVID-19 when compared with its previously approved bivalent COVID-19 vaccine.
Simply Wall St.
Moderna (NASDAQ:MRNA) shareholders are still up 857% over 5 years despite pulling back 6.1% in the past week
Long term investing can be life changing when you buy and hold the truly great businesses. And highest quality...
ACCESSWIRE
Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company’s Next Generation COVID-19 Vaccine
mRNA-1283 met its primary vaccine efficacy endpoint in a Phase 3 trial, demonstrating non-inferior vaccine efficacy against COVID-19 compared to Spikevax® in participants 12 years of age and older Higher efficacy was observed in mRNA-1283 compared ...